Clinical trials: Type 1 or 2 Diabetes
Diabetes Mellitus, Type 2
A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus
The purpose of this study is to help answer the following research question(s): To test if taking LY2599506 for 12 weeks controls blood sugar better than taking glyburide for 12 weeks.
- Trial name
- NCT01029795
- Testing
- LY2599506, Glyburide
- Where
- 16 sites in Australia, Austria and 5 more
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Diabetes, Diabetes Mellitus, Type 1
Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus
This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00806858
- Testing
- NovoPen® 4
- Where
- China
- Volunteers
- 526 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type I or Type II Diabetes (Excludes Gestational Diabetes)
Empowering Patients to Better Manage Diabetes Through Self-Care
This study will look at the impact of health insurance benefits on self management of diabetes for people with this condition. Studies have shown that when people with diabetes manage their disease better, they stay healthier.
- Trial name
- NCT00254501
- Testing
- Pharmacist Counseling, Educational materials
- Volunteers
- 69 people
- Sponsor
- Oregon State University
Diabetes Mellitus, Diabetic Nephropathy
Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
The purpose of this study is to evaluate the safety and tolerability of two dosing regimens of FG-3019 administered over 12 weeks in patients with diabetic nephropathy and proteinuria on background angiotensin converting enzyme…
- Trial name
- NCT00754143
- Testing
- FG-3019
- Where
- 18 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kyntra Bio
Diabetes Mellitus
Changes in Arterial Stiffness and Endothelial Glycocalyx in Patients With Poorly Controlled Diabetes Mellitus Type 1 or Type 2 After Optimization of Antidiabetic Medication.
Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity.
- Trial name
- NCT03010956
- Where
- Greece
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Athens
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of…
- Trial name
- NCT00948493
- Testing
- Buccal insulin spray
- Sponsor
- Generex Biotechnology Corp.
Type 1 Diabetes
Automated Overnight Closed-loop Glucose Control in Young People With Type 1 Diabetes
Children and adolescents with type 1 diabetes need regular insulin injections or continuous insulin delivery with an insulin pump in order to keep blood sugar levels normal.
- Trial name
- APCam05 (NCT00989898)
- Testing
- Automated closed-loop insulin delivery
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Cambridge
Diabetes, Diabetes Mellitus, Type 1
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess and compare the effect on blood sugar control of insulin detemir and insulin aspart or insulin detemir alone administered…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00773279
- Testing
- FlexTouch®, FlexPen®
- Where
- 65 sites in United States
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
Primary: To compare the efficacy and safety of Insulin Glulisine to Insulin Lispro in subjects with type 1 or type 2 diabetes mellitus. To compare the frequency of hypoglycemia of Insulin Glulisine to Insulin Lispro.
- Trial name
- NCT00467376
- Testing
- Insulin Glulisine, Lispro, Insulin Glargine
- Where
- China
- Volunteers
- 485 people
- Sponsor
- Sanofi
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- Lenbelintide
- Where
- 220 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Coronary Heart Disease
Long-term Mortality in Diabetics Undergoing Major Surgery
Patients with CAD and diabetes mellitus have a better prognosis than patients with CAD and no diabetes mellitus. In acute coronary syndrome patients with an insulin therapy had a better survival than patients with oral…
- Conditions
- Diabetes Mellitus, Coronary Heart Disease, Major Non-cardiac Surgery
- Trial name
- NCT00286572
- Where
- Switzerland
- Volunteers
- 380 people
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00665093
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,569 people
- Sponsor
- Novo Nordisk A/S
Adult Patients With Type 2 Diabetes
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and…
- Trial name
- NCT06871761
- Testing
- HR17031 injection, insulin glargine
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes, Overweight or Obesity
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT05814107
- Testing
- CT-996
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Carmot Australia First Pty Ltd
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® INHALE-1 Study in Pediatrics
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine…
- Trial name
- INHALE-1 (NCT04974528)
- Testing
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Mannkind Corporation
Diabetic Retinopathy
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic…
- Trial name
- CANBERRA (NCT04265261)
- Testing
- RG7774
- Where
- 68 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of the trial is to investigate safety and efficacy of semaglutide once weekly in monotherapy or in combination with one OAD (oral anti-diabetic drug) in Japanese subjects with type 2…
- Trial name
- SUSTAIN™ (NCT02207374)
- Testing
- semaglutide, DPP-4 inhibitor
- Where
- 43 sites in Japan
- Volunteers
- 601 people
- Sponsor
- Novo Nordisk A/S